📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. (2022)

First Author: RECOVERY Collaborative Group

Attributed to: Phase 1 COVID-19 Data and Connectivity – National Core Study (Phase 1 D&C-NCS) funded by COVID

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s0140-6736(22)00163-5

PubMed Identifier: 35151397

Publication URI: http://europepmc.org/abstract/MED/35151397

Type: Journal Article/Review

Volume: 399

Parent Publication: Lancet (London, England)

Issue: 10325

ISSN: 0140-6736